A Comparitive Study Between Magnesium Sulphate Versus Dexamethasone as an Adjuvant to Bupivacaine in Supraclavicular Brachial Plexus Block
Keywords:Magnesium Sulphate, Dexamethasone, Supraclavicular Brachial plexus block
Introduction: Magnesium Sulphate and Dexamethasone are used as adjuvants to local anaesthetics in
regional anaesthesia to improve the quality of block
Objective: To compare the efficacy of magnesium sulphate and dexamethasone on the characteristics of the
block and its effect on postoperative analgesia when added as an additive to bupivacaine in supraclavicular
brachial plexus block.
Materials and Methods: Fifty patients belonging to American Society of Anaesthesiologists (ASA) Grade
I and II, aged between 18 to 55 years, scheduled for elective upper limb surgeries under supraclavicular
brachial plexus block were enrolled in this study. Patients were equally divided into two groups : group M
received 0.5% Bupivacaine 30ml with 10% Magnesium sulphate 5 ml (500mg) and group D received 0.5%
Bupivacaine 30ml with Dexamethasone 2ml (8mg) + Normal saline 3ml. Onset and duration of sensory and
motor block , duration of postoperative analgesia and any complications were observed.
Results: In our study the demographic profile of patients, duration of surgery and ASA status between the
two groups were comparable. Onset of sensory block was earlier in group D than group M (17.12±0.93
minutes and 19.40 ±1.08 minutes respectively, p=0.001). Duration of motor block and analgesia were longer
in group D as compared to group M (479.00 ±50.83 minutes vs 346.40 ±32.77 minutes respectively, p=
0.001 for motor block and 533.80 ±59.80 minutes vs 415.00 ±57.23 minutes respectively, p=0.001 for
analgesia). No significant side effects were noted.
Conclusion: Dexamethasone is a better adjuvant than Magnesium Sulphate when added to bupivacaine in
supraclavicular brachial plexus block as it prolongs duration of motor block and analgesia significantly with
minimal side effects.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions